Oncolytics Biotech stock tracks REO 033 progress toward year end
Published on 10/05/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Oncolytics Biotech stock was last at USD 0.63 on Nasdaq on October 2, 2026, with the quote down 1.59 percent from the prior session. The company said on September 28 that its REO 033 colorectal cancer study had activated substantially all planned Part A sites and was moving toward an interim clinical update by year-end 2026, according to StockTitan.
REO 033 moves toward data
REO 033 is a randomized study testing pelareorep with FOLFIRI and bevacizumab against FOLFIRI and bevacizumab alone in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Objective response rate is the primary endpoint, while progression-free survival, overall survival, safety and biomarker analyses are additional endpoints.
The September 28 update places enrollment and trial execution ahead of the next valuation checkpoint. The company expects the number of evaluable patients enrolled by the end of October to determine whether Part A data can support an interim update before the end of 2026, according to StockTitan.
Six month finances tighten
For the six months ended June 30, 2026, Oncolytics reported a net loss of USD 18.685 million, up 87.1 percent from USD 9.988 million in the prior-year period. Operating expenses reached USD 18.660 million, compared with USD 9.672 million a year earlier, according to MetaTrader.
Cash and cash equivalents were USD 4.115 million at June 30, 2026, down 61.6 percent from USD 10.721 million a year earlier. Net cash used in operating activities was USD 15.431 million, compared with USD 8.839 million in the prior-year period, making financing capacity a central counter-factor as the study advances.
Consensus target stays far above quote
MarketBeat lists one Strong Buy, one Buy and one Sell rating, producing a Moderate Buy consensus and a USD 5.00 target price. The target lies 693.7 percent above the USD 0.63 quote, according to MarketBeat.
ONCY stays near yearly low
ONCY was last at USD 0.63 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, 55.6 percent below its 52-week high of USD 1.42 and USD 0.01 above its 52-week low of USD 0.62. Market capitalization was USD 63.3 million and volume was 611,814 shares on that session.
Oncolytics Biotech stock facts
- Company: Oncolytics Biotech Inc.
- Ticker: ONCY
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 0.63
- Market capitalization: USD 63.3 million (as of October 2, 2026)
- 52-week range: USD 0.62-1.42 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
